Emergent BioSolutions (NYSE:EBS) Downgraded to Hold Rating by StockNews.com

StockNews.com downgraded shares of Emergent BioSolutions (NYSE:EBS) from a buy rating to a hold rating in a report issued on Friday morning.

Several other analysts have also recently weighed in on the stock. Benchmark upped their price objective on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. Rodman & Renshaw restated a “buy” rating and set a $16.00 price target on shares of Emergent BioSolutions in a research report on Friday, September 13th.

Emergent BioSolutions Stock Up 0.5 %

Shares of NYSE EBS opened at $8.10 on Friday. Emergent BioSolutions has a 52-week low of $1.42 and a 52-week high of $15.10. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.47 and a current ratio of 2.88. The business has a fifty day moving average of $9.30 and a two-hundred day moving average of $8.82. The stock has a market cap of $438.89 million, a PE ratio of -1.98 and a beta of 1.59.

Hedge Funds Weigh In On Emergent BioSolutions

A number of institutional investors have recently modified their holdings of EBS. Meeder Asset Management Inc. acquired a new stake in shares of Emergent BioSolutions in the second quarter valued at approximately $41,000. Verus Capital Partners LLC bought a new position in Emergent BioSolutions in the 2nd quarter valued at $68,000. Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Emergent BioSolutions in the 2nd quarter valued at $93,000. Stifel Financial Corp bought a new stake in shares of Emergent BioSolutions during the third quarter worth $96,000. Finally, Morse Asset Management Inc acquired a new position in shares of Emergent BioSolutions during the second quarter valued at $97,000. 78.40% of the stock is owned by institutional investors.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.